BOGOTA, Colombia – Brazil's health surveillance agency, Anvisa, approved the commercialization of Sylvant (siltuximab) to treat patients with multicentric Castleman's disease (MCD) who do not have HIV and the human herpesvirus-8 infection. The application was filed by Sao Paulo-based Janssen-Cilag Farmacêutica, a subsidiary of Belgium's Janssen Pharmaceutical, which in turn is owned by Johnson & Johnson, of New Brunswick, N.J.